Clinical Trials
12 trialsNCT06561347 2026-03-31
ZEBRA
Massachusetts General Hospital
Phase 2 Recruiting
NCT01479842 2026-03-23
Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT04624906 2026-02-04
BRAWM
Sunnybrook Health Sciences Centre
Phase 2 Active not recruiting
NCT07259122 2025-12-02
ZBR in WM
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Not yet recruiting
NCT07169565 2025-09-11
Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Not yet recruiting
NCT06942507 2025-04-30
BRZ-WM
Peking Union Medical College Hospital
Phase NA Not yet recruiting
NCT05914662 2024-08-28
ZBR
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
NCT05979948 2023-09-14
CZ-WM01
Shanghai Changzheng Hospital
Phase 2 Unknown
NCT02257242 2023-02-09
BRiM
Brown University
Phase 1 Completed
NCT01429025 2019-10-08
Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma
Alliance for Clinical Trials in Oncology
Phase 1 Completed
NCT02168907 2018-07-02
CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Wake Forest University Health Sciences
Phase 1 Terminated
NCT01110135 2017-05-24
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma
University of Washington
Phase 2 Completed